France Introduces Fast Track Pathway to Accelerate Clinical Trial Data Generation

France is taking steps to accelerate the generation of clinical trial data through a new fast track authorisation pathway designed to speed up early stage studies. The initiative, led by the French medicines regulator ANSM, aims to reduce approval timelines for certain clinical trials while maintaining scientific and ethical oversight.

Under the scheme, selected mono national trials conducted in France may receive regulatory approval within as little as 14 days if no additional questions arise during the evaluation process. Trials that require further review may still be authorised within approximately 49 days.

The fast track pathway is expected to focus on early phase studies, first in class therapies, and research targeting serious or rare diseases where limited treatment options exist. It may also support trials that include adolescent patients alongside adult populations.

Health authorities believe the measure will help strengthen France’s position as a competitive destination for biomedical research and encourage faster development of innovative therapies. By shortening approval timelines, researchers and pharmaceutical companies could generate clinical data more rapidly, potentially accelerating the path toward new treatment options for patients.